MAPT and Alzheimer disease: While an enhanced understanding of the two characteristic pathological changes seen in AD – plaques composed of amyloid β (Aβ) and neurofibrillary tangles (NFTs) composed of hyperphoshorylated tau – have yielded targets that may be amenable to pharmacological intervention, no therapeutics with potentially disease-modifying properties have advanced past Phase III trials.